河化股份(000953.SZ)：预计2025年归母净利润600万元-900万元，同比下降92.43%-88.64%

Core Viewpoint - The company expects a significant decline in net profit attributable to shareholders for the year 2025, primarily due to the absence of non-recurring gains that were present in the previous year [1] Financial Performance Summary - The projected net profit for the year 2025 is estimated to be between 6 million to 9 million yuan, representing a year-on-year decrease of 92.43% to 88.64% [1] - The net profit after deducting non-recurring gains is expected to be between 5.7 million to 8.5 million yuan, indicating a year-on-year increase of 46.51% to 118.49% [1] Reasons for Performance Changes - The decline in net profit is attributed to the absence of approximately 76 million yuan in non-recurring gains from a urea production capacity transfer transaction that occurred in 2024 [1] - The subsidiary, Nansong Pharmaceutical, has been actively expanding its market presence and controlling various period expenses, which has contributed to the growth in net profit after excluding non-recurring items [1]